Azz....+16%
....ma ci sono news sulle condizioni dell'offering, o cosa!?
....
una botta di vita, in realtà l'unica notizia recente è di ieri ed è questa:
Novavax Announces Closing of $175.25 Million Offering of Convertible Senior Notes Due 2027 and $74.75 Million Public Offering of Common Stock.
Novavax Announces Closing of $175.25 Million Offering of Convertible Senior Notes Due 2027 and $74.75 Million Public Offering of Common Stock
Dec 28, 2022
GAITHERSBURG, Md., Dec. 28, 2022 /
PRNewswire/ -- On December 20, 2022, Novavax, Inc. (Nasdaq: NVAX)
, a biotechnology company (the "Company" or "Novavax") dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, completed the closing of its previously announced offering of $150 million aggregate amount of 5.00% Senior Convertible Notes due 2027 (the "Notes"), and on December 23, 2022, the Company completed the closing of the initial purchasers' option to purchase up to an additional $25.25 million aggregate principal amount of the Notes, which was exercised in full. On December 20, 2022, the Company also completed the closing of its previously announced underwritten public offering of 7,475,000 shares of its common stock, including the exercise in full of the underwriters' option to purchase up to an additional 975,000 shares of its common stock (the "Common Stock Offering") resulting in total gross proceeds of $74.75 million. Total combined gross proceeds to the Company from both the offering of Notes and the Common Stock Offering was $250 million.
The Notes were offered and sold only to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). J.P. Morgan, Jefferies and Cowen acted as joint book-running managers and representatives of the initial purchasers for the offering of the Notes. J. Wood Capital Advisors served as financial advisor to the Company in relation to the offering of the Notes.
The Notes bear cash interest at a rate of 5.00%, payable on June 15 and December 15 of each year, beginning on June 15, 2023. The Notes will be redeemable, in whole or in part (subject to certain limitations), for cash at Novavax' option at any time, and from time to time, on or after December 22, 2025, if the last reported sale price of Novavax' common stock has been at least 130% of the conversion price then in effect for at least 20 trading days (whether or not consecutive), during any 30 consecutive trading day period (including the last trading day of such period) ending on and including the trading day immediately preceding the date on which Novavax provides notice of redemption at a redemption price equal to 100% of the principal amount of the Notes to be redeemed, plus any accrued and unpaid interest to, but excluding, the redemption date. The Notes are convertible at an initial conversion rate of 80.0000 shares of the Company's common stock per $1,000 principal amount of Notes, which is equivalent to an initial conversion price of $12.50 per share of Novavax' common stock, representing a 25% conversion premium of the public offering price in the Company's concurrent common stock offering that closed on December 20, 2022. The Company will settle conversions by paying or delivering, as applicable, cash, shares of common stock, or a combination of cash and shares of common stock, at the Company's election.
Novavax estimates that the net proceeds from the offering of the Notes are approximately $166.3 million, after deducting the initial purchasers' discounts and commissions and estimated offering expenses.
The offer and sale of the Notes and any shares of common stock issuable upon conversion of the Notes have not been, and will not be, registered under the Securities Act or any other securities laws, and the Notes and any such shares cannot be offered or sold absent registration or except pursuant to an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and any other applicable securities laws.
For the Common Stock Offering, shares were issued at $10.00 per share, resulting in total gross proceeds from the Common Stock Offering of $74.75 million before deducting the underwriters' discount and offering expenses. J.P. Morgan, Jefferies and Cowen acted as joint book-running managers and representatives of the underwriters for the Common Stock Offering. B. Riley Securities and H.C. Wainwright & Co. acted as co-lead managers for the Common Stock Offering.
Novavax estimates that the net proceeds from the Common Stock Offering are approximately $69.8 million, after deducting the underwriters' discounts and commissions and estimated offering expenses.
A registration statement relating to the Common Stock Offering was filed with the Securities and Exchange Commission ("SEC") on March 11, 2020, and is effective. The Common Stock Offering was made by means of a prospectus supplement and the accompanying prospectus. An electronic copy of the preliminary prospectus supplement and accompanying prospectus relating to the Common Stock Offering are available on the SEC's website at
www.sec.gov, and may also be obtained from: J.P. Morgan, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at (866) 803-9204 or by email at
prospectus-eq_fi@jpmchase.com; Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, by telephone at (877) 821-7388 or by email at
prospectus_department@jefferies.com; or Cowen and Company, LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, Attn: Prospectus Department, by telephone at (833) 297-2926, or by email at
PostSaleManualRequests@broadridge.com.